Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 12;13(2):25579.
doi: 10.52965/001c.25579. eCollection 2021.

Risdiplam for the Use of Spinal Muscular Atrophy

Juyeon Kakazu  1 , Nakoma L Walker  2 , Katherine Claire Babin  2 , Katherine A Trettin  2 , Christopher Lee  3 , Patricia B Sutker  4 , Adam M Kaye  5 , Alan D Kaye  6
Affiliations
Review

Risdiplam for the Use of Spinal Muscular Atrophy

Juyeon Kakazu et al. Orthop Rev (Pavia). .

Abstract

Spinal muscular atrophy (SMA) is one of the leading causes of death in infants related to the degeneration of neurons. Currently, there are no curative treatment options for SMA, and many options available may not be feasible. This review presents the background, clinical studies, and indications for the use of Risdiplam in treating SMA. SMA causes a decrease in the production of survival motor neuron proteins (SMN) and current treatments target to increase the expression of SMN. Risdiplam is the first and only oral medication to be approved to treat SMA. As an SMN2 splicing modifier, it has provided stronger systemic therapies than previous intrathecal and gene replacement therapies. There have been many efforts to treat SMA with multidisciplinary approaches. These include intrathecal injections to gene replacement therapies. However, these have been faced with limitations such as reaching a good therapeutic dose in systemic tissues, route of administration, and price. Risdiplam is currently the only orally administered drug approved by the FDA for the treatment of SMA. It not only provides a good therapeutic window to systemic tissues but allows for a non-invasive approach in infants. Further investigation and comparison on the safety profile of Risdiplam due to its broader systemic effect should be considered with other available therapies.

Keywords: evrysdi; nusinersen; risdiplam; sma; spinal muscular atrophy.

PubMed Disclaimer

References

    1. 1. Smith M, Calabro V, Chong B, Gardiner N, Cowie S, du Sart D. Population screening and cascade testing for carriers of SMA. Eur J Hum Genet. 2007;15(7):759-766. doi:10.1038/sj.ejhg.5201821 - PubMed
    1. 2. Farrar MA, Kiernan MC. Spinal Muscular Atrophy. In: eLS. John Wiley Sons, Ltd; 2011.
    1. 3. Kugelberg E, Welander L. Heredofamilial juvenile muscular atrophy simulating muscular dystrophy. AMA Arch Neurol Psychiatry. 1956;75(5):500-509. doi:10.1001/archneurpsyc.1956.02330230050005 - PubMed
    1. 4. Farrar MA, Vucic S, Johnston HM, Ee Du Sart D, Kiernan MC. Pathophysiological Insights Derived by Natural History and Motor Function of Spinal Muscular Atrophy. J Pediatr. 2013;162:155-159. doi:10.1016/j.jpeds.2012.05.067 - PubMed
    1. 5. Markowitz JA, Tinkle MB, Fischbeck KH. Spinal muscular atrophy in the neonate. JOGNN - J Obstet Gynecol Neonatal Nurs. 2004;33(1):12-20. doi:10.1177/0884217503261125 - PubMed